SUMMARY Platelet aggregation was studied in citrated whole blood by an electrical impedance method. Blood samples from normal volunteers were studied with the aim of finding a suitable method for the routine study of samples from patients. An erratic tracing and low maximum aggregation were seen in samples with a high normal haematocrit. Optimal aggregation was seen when blood was diluted to a haematocrit of *300; isotonic saline was a better diluent than platelet poor plasma. No appreciable differences were seen when the platelet count was diluted down to 50 x 109/l, after which there was a progressive reduction in response. Dose response curves were obtained, and normal ranges for ADP, collagen, and sodium arachidonate were determined. Acetylsalicylic acid had a more pronounced effect on ADP aggregation than on collagen. Prostacyclin (Epoprostenol) and the synthetic prostacyclin analogue ZK 36,374 both showed dose dependent inhibition of aggregation, but the duration of effect of the latter was much longer (> 6 h).
For the last 20 years platelet aggregation has been studied extensively by optical methods using platelet rich plasma and turbidometric devices.' Although of proved diagnostic value, these systems have certain limitations. Centrifugation is required for sample preparation so that red cells, white cells, and some of the heavier platelets are removed from the final platelet suspension to be tested. These other blood cells are probably important modulators of platelet function in vivo since they actively take up adenine nucleotides, synthesise and release regulatory prostaglandins, and may preferentially bind prostacyclin.24 Substances that regulate platelet function such as prostacyclin and cyclic AMP may degrade to biologically inactive products in the time required for platelet rich plasma preparation.
The recent innovation of electronic aggregation by the impedance method in whole blood circumvents most of these problems.5 With this system, blood may be analysed immediately after sampling without centrifugation and aggregation can be investigated in the presence of all blood elements. Most reports describe whole blood platelet aggregation in blood from laboratory animals; we have studied the application of this method to human blood in a routine coagulation laboratory.
Accepted for publication 24 March 1984 Material and methods Blood was obtained from apparently healthy adult human volunteers, who had not taken any anti platelet drugs for at least two weeks before sampling. Blood was anticoagulated with 3 13% tri-sodium citrate, nine parts blood to one part anticoagulant. A full blood count and platelet count were performed using a Coulter S Plus IV (Coulter Electronics Ltd, Luton, Beds). Normal subjects were also studied after ingesting varying doses of acetylsalicylic acid. 
INFLUENCE OF HAEMATOCRIT
Aggregation was also performed on undiluted whole blood and after diluting with isotonic saline or platelet poor plasma to reduce the haematocrit. Both normal and polycythaemic samples were studied to create a wide range of haematocrits between *100 and *600. 
PLATELET COUNT
Two thrombopenic subjects (platelets <25 x 109/l) were bled to study the effect of platelet count. Whole blood platelet aggregation in these subjects was barely detectable using collagen or ADP. Varying amounts of platelet rich plasma from normal (blood group compatible) donors were diluted in citrated whole blood from thrombopenic patients and the volume corrected with platelet poor plasma to give a range of final platelet counts, at a constant haematocrit of *30p. Alternatively, a 975 ,l aliquot of thrombopenic dlood was allowed to settle for 20 min and a volume of platelet rich plasma was removed and replaced with platelet rich plasma from a normal donor.
REPRODUCIBILITY
Precision was studied using normal blood and repeating aggregation to one reagent on the same sample.
INHIBITORS
The effects of adding prostacyclin (Epoprostenol, Weilcome Pharmaceuticals) and the stable prostacyclin analogue ZK 36,374 (Schering Chemicals Ltd) were studied by adding varying concentrations to whole blood before the addition of aggregating reagents. The dose (ID,0) causing a 50% reduction in response to agonists was estimated.
Results
As expected, low stirring speeds produced poor aggregation responses; optimal aggregation occurred at about 600 rpm. Higher stirring speeds showed a gradual reduction in the total impedance change.
Changes in haematocrit produced dramatic effects on impedance (Fig. 1) . High haematocrits caused erratic tracings and often minimal aggregation with poor precision, while large dilutions with saline also caused a reduction in platelet count, which also decreased the aggregation response. Dilution to a haematocrit of *300 appeared to be optimal; this gave a better wave of aggregation and a less erratic trace than seen with neat whole blood while causing a minimal decrease in platelet numbers. This also enabled standardisation of whole blood aggregation from different subjects. Saline appeared to be the diluent of choice, giving a steeper and more regular trace than platelet poor plasma.
Reduction of the platelet count by dilution of platelet rich plasma in thrombopenic blood showed no significant changes in aggregation down to platelet counts of about 50 x 109/l. Below this value a progressive reduction in the response was seen (Fig. 2) . Reproducibility testing showed a coefficient of variation between 15% and 20%, depending on the sample used and the dose of aggregating reagent; poor aggregation waves tended to be less reproducible.
Good aggregation responses could be obtained with collagen at concentrations of 1-5 ug/ml (Fig.  3) . Aggregation with ADP required doses about 10 times higher than those routinely used for platelet rich plasma aggregation (Fig. 3) (Fig. 4) .
The addition of prostacyclin immediately before aggregation led to a dose dependent inhibition of aggregation with an S-shaped dose response curve, giving an ID,, of about 1 ng/ml for 5 ,g/ml collagen. Addition of ZK 36,374 to whole blood produced a similar dose dependent inhibitory response, giving
an ID50 of about 1-75 ng/ml for 5 ,ug/ml collagen.
Neither inhibitor was able to abolish completely the response to collagen, even with very high doses, whereas both agents could completely block ADP aggregation using relatively low inhibitor concentrations. Time course studies showed that the inhibitory effect of prostacyclin disappeared rapidly within 30-60 min after incubation with whole blood (Fig.  5) , whereas the inhibitory effect of ZK 36,374 was stable in whole blood for at least 6 h.
Discussion
Many of the studies of whole blood impedance The weak effect of acetylsalicylic acid on collagen aggregation has been described previously8 and is believed to be due to the ability of the impedance method to detect even very small platelet aggregates which may still form in the presence of acetylsalicylic acid. Prostacyclin and the stable prostacyclin analogue ZK 36,374, however, caused a marked inhibition of both ADP and collagen aggregation, at doses of the same order of magnitude as those active in platelet rich plasma. Prostacyclin was only effective in whole blood for short incubation periods, showing the usefulness of this technique for ex-vivo studies of substances with short half lives. The discrepancy-between duration of effect of prostacyclin and ZK 36,374 is probably related to the nonenzymatic degradation of prostacyclin at pH 7*4 to biologically inactive metabolites9; ZK 36,374 is chemically stable and although possibly adsorbed to the red cell surface does not appear to be appreciably inactivated in whole blood ex vivo.'°I n summary, we recommend the following for routine clinical work: collection of blood into citrate and dilution to a haematocrit of *300 with isotonic saline; stirrer speed 600 rpm; 975 ul blood plus 25 Iul agonist (12.5 and 25 uM ADP, 1 and 5 ug/ml collagen, 0-5 and lmM sodium arachidonate); chart speed 2 cm/min; and 5 ohm equal to 2-5 cm of chart paper.
The value of whole blood aggregation in the clinical laboratory remains to be seen. There may be important uses in the study of hypercoagulable states; antiplatelet treatment; and disorders of red and white cells, such as sickle cell crisis, infection, and the leukaemias. These possible applications are currently under study in our laboratory and will be reported elsewhere.
